Aquinox Pharmaceuticals Inc. (AQXP) Has Plunged To A New Low After Study Failed
Markets2018-06-27
9 Views
Aquinox Pharmaceuticals Inc. (AQXP) announced Wednesday morning that its Phase 3 clinical trial of once-daily, oral rosiptor, for the treatment of interstitial cystitis/bladder pain syndrome, failed to meet its primary endpoint.
Source: RTTNews
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Should You Leverage Affiliate Marketing for Your E-Commerce Store?
